» Articles » PMID: 20840586

Proteoglycans in Health and Disease: New Concepts for Heparanase Function in Tumor Progression and Metastasis

Overview
Journal FEBS J
Specialty Biochemistry
Date 2010 Sep 16
PMID 20840586
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Heparanase is an endo-β-D-glucuronidase capable of cleaving heparan sulfate side chains at a limited number of sites, yielding heparan sulfate fragments of still appreciable size. Importantly, heparanase activity correlates with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of heparan sulfate cleavage and remodeling of the extracellular matrix and basement membrane underlying epithelial and endothelial cells. Similarly, heparanase activity is implicated in neovascularization, inflammation and autoimmunity, involving the migration of vascular endothelial cells and activated cells of the immune system. The cloning of a single human heparanase cDNA 10 years ago enabled researchers to critically approve the notion that heparan sulfate cleavage by heparanase is required for structural remodeling of the extracellular matrix, thereby facilitating cell invasion. Progress in the field has expanded the scope of heparanase function and its significance in tumor progression and other pathologies. Notably, although heparanase inhibitors attenuated tumor progression and metastasis in several experimental systems, other studies revealed that heparanase also functions in an enzymatic activity-independent manner. Thus, inactive heparanase was noted to facilitate adhesion and migration of primary endothelial cells and to promote phosphorylation of signaling molecules such as Akt and Src, facilitating gene transcription (i.e. vascular endothelial growth factor) and phosphorylation of selected Src substrates (i.e. endothelial growth factor receptor). The concept of enzymatic activity-independent function of heparanase gained substantial support by the recent identification of the heparanase C-terminus domain as the molecular determinant behind its signaling capacity. Identification and characterization of a human heparanase splice variant (T5) devoid of enzymatic activity and endowed with protumorigenic characteristics, elucidation of cross-talk between heparanase and other extracellular matrix-degrading enzymes, and identification of single nucleotide polymorphism associated with heparanase expression and increased risk of graft versus host disease add other layers of complexity to heparanase function in health and disease.

Citing Articles

Inflammation-Associated Cytotoxic Agents in Tumorigenesis.

Arnhold J Cancers (Basel). 2024; 16(1).

PMID: 38201509 PMC: 10778456. DOI: 10.3390/cancers16010081.


Heparanase-A single protein with multiple enzymatic and nonenzymatic functions.

Vlodavsky I, Kayal Y, Hilwi M, Soboh S, Sanderson R, Ilan N Proteoglycan Res. 2023; 1(3):e6.

PMID: 37547889 PMC: 10398610. DOI: 10.1002/pgr2.6.


Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction.

Yerukala Sathipati S, Tsai M, Shukla S, Ho S HGG Adv. 2023; 4(3):100190.

PMID: 37124139 PMC: 10130501. DOI: 10.1016/j.xhgg.2023.100190.


Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells.

Sioud M, Olberg A Cancers (Basel). 2023; 15(7).

PMID: 37046595 PMC: 10093763. DOI: 10.3390/cancers15071934.


Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X Mol Cancer. 2023; 22(1):48.

PMID: 36906534 PMC: 10007858. DOI: 10.1186/s12943-023-01744-8.


References
1.
Ford A, Grandis J . Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 2002; 25(1):67-73. DOI: 10.1002/hed.10224. View

2.
Joyce J, Freeman C, Meyer-Morse N, Parish C, Hanahan D . A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 2005; 24(25):4037-51. DOI: 10.1038/sj.onc.1208602. View

3.
Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S, Kleinman H . Heparanase regulates murine hair growth. Am J Pathol. 2005; 166(4):999-1008. PMC: 1602387. DOI: 10.1016/S0002-9440(10)62321-8. View

4.
Sanderson R, Yang Y . Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2007; 25(2):149-59. PMC: 3633534. DOI: 10.1007/s10585-007-9125-3. View

5.
Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N . Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod Pathol. 2009; 22(12):1548-54. DOI: 10.1038/modpathol.2009.115. View